Lexology June 29, 2022
Knobbe Martens

On June 15, 2022, Boston Scientific entered into a definitive agreement to purchase a majority stake in M.I.Tech Co., Ltd, a publicly traded Korean medical device company in the field of endoscopic and urological procedures. The agreement includes a purchase price of approximately $230 million. According to the announcement, M.I.Tech is the creator of the HANAROSTENT® technology, a family of conformable, non-vascular, self-expanding metal stents. Non-vascular stents can be used in gastrointestinal applications and in airways to clear obstructions or constrictions in areas such as the biliary tree, pancreatic duct, esophagus, colon, and duodenum.

Boston Scientific’s Art Butcher, executive vice president and group president, MedSurg and Asia Pacific, stated:

M.I.Tech is an innovator in non-vascular stent development, with product...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Medical Devices, Mergers & Acquisitions / JV, Trends
Related Articles:
Exo adds FDA-cleared AI tools to handheld ultrasound system
FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices
FDA launches initiative to advance home healthcare models, devices
Is Telepathy Possible? Perhaps, Due To New Technology
FDA Proposes Updated Guidance Concerning Cybersecurity of Medical Devices

Share This Article